ForPatients

by Roche

Crohn's Disease

RVT-3101 for the Treatment of Moderate to Severe Active Crohn's Disease

Trial Status Trial Runs In Trial Identifier
Active, not recruiting 10 Countries NCT05910528 GA45392

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This Phase 2, randomized, double-blind, multicenter, induction and maintenance study is designed to evaluate the safety and efficacy of RVT-3101 in adult participants with moderate to severe active Crohn's disease.

Hoffmann-La Roche Sponsor	Phase 2 Phase	
NCT05910528 GA45392 Trial Identifiers		
Eligibility Criteria:		
Gender All	Age >=18 Years & <= 75 Years	Healthy Volunteers